You might not expect a diabetes drug to change what’s in your wine glass. But something unusual is happening at the intersection of health, habit, and hospitality — and it’s got the whole beverage world paying attention.

Over the past year, Ozempic and similar semaglutide-based medications (like Wegovy and Rybelus) have become some of the most talked-about names in health and weight loss. Originally developed for type 2 diabetes, these GLP-1 receptor agonists are now being quietly linked to another shift: a surprising drop in alcohol consumption. And the effects are being felt far beyond the pharmacy.

There hasn’t been any focused research on the use of weight-loss medications in Turkey yet. But in the U.S., the topic is already at the top of the public health conversation — from medical journals to bar counters. We’ve prepared this piece as an early reflection, knowing that the discussion will likely grow louder here, too, in the near future.

So What Does a “Fullness Hormone” Have to Do with a Glass of Wine?

GLP-1 drugs mimic a hormone that slows digestion, reduces appetite, and signals satiety. But the appetite they suppress isn’t just for food.

Across the board, users are reporting strong aversions to alcohol — sometimes just days or weeks after starting the drug. For some, it’s an uncomfortable nausea. For others, it’s a fading desire. Red wine seems to be the most common trigger. But the shift isn’t limited to type or taste — it’s about the experience itself.

Less Sugar, Less Wine, Less Buzz

One of the clearest changes? Sugar cravings drop. And with that, the natural bridge to wine — especially sweet or high-alcohol reds — starts to collapse. Some users say even one glass is too much. Others mention a change in how alcohol feels, physically and mentally. The appeal simply… fades. Even those who previously enjoyed wine regularly are pausing, cutting back, or reaching for something lighter — or alcohol-free altogether.

A Quiet Shift in Bars and Bottles

These personal changes are rippling outward. In the U.S., wine club memberships are down — some by as much as 50%. Sommeliers and bartenders report earlier drinking hours, smaller pours, fewer sugary cocktails, and rising demand for low- or no-alcohol options.

Just a Side Effect — or a Sign of the Times?

Some believe this is less about Ozempic alone and more about a larger shift in behavior. People are choosing wellness. The pandemic reset habits. Younger generations are drinking less. Cannabis, CBD, and zero-proof options are on the rise. And now, GLP-1 medications are pushing things further.
What was once a regular glass of wine is becoming a more intentional choice.

So What Now? Ozempic doesn’t tell us to stop drinking. But it asks us new questions:

Do we still enjoy it? When? How much? And why?

These aren’t bad questions to ask — for the drinker, or for the industry. Whether you run a wine bar or pour a single glass at home, this isn’t just about what’s on the menu. It’s about the way we relate to pleasure, choice, and what we crave. ne kadar?

And right now, all of it is evolving.